Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
R.P. Insinga
Observed names:
R Insinga,
R P Insinga,
R. Insinga,
RP Insinga
Observed institutions:
Merck & Co., Inc., Rahway, NJ, USA (United States),
University of Wisconsin–Madison
OpenAlex ID:
A5111920477
The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK
2008
·
EJ Dasbach
, RP Insinga
, et al.
·
BJOG An International Journal of Obstetrics & Gynaecology
·
87
Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years
2017
·
A. Modi
, S. Sajjan
, et al.
·
Osteoporosis International
·
37
Pcn345 - Health State Utilities in Metastatic Nsclc: a Study of Multiple Immuno-oncology Trials
2018
·
M. Huang
, S. Chandwani
, et al.
·
Value in Health
·
12
PCN64 Cost-Effectiveness of Pembrolizumab (KEYTRUDA®) in Combination with Chemotherapy for First-LINE Treatment of Metastatic Squamous NON-SMALL Cell LUNG Cancer (NSCLC) in France
2020
·
C. Chouaid
, L. Bensimon
, et al.
·
Value in Health
·
9
PCN41 Cost-Effectiveness of Pembrolizumab in Combination with Chemotherapy in the 1ST LINE Treatment of Metastatic NSCLC in Taiwan
2020
·
R. Insinga
, A. Arunachalam
, et al.
·
Value in Health Regional Issues
·
9
PDF
Trends in malignant melanoma incidence and mortality in Wisconsin, 1979-1997.
2001
·
R P Insinga
, E N Reither
, et al.
·
PubMed
·
9
Pcn194 Cost-effectiveness Analysis of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Previously Untreated Patients With Metastatic Squamous Non-small Cell Lung Cancer in England
2019
·
T. Harding
, H. Dawson
, et al.
·
Value in Health
·
3
Impact of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-like Particle Vaccine in a Sexually Active Population of North American Women
2008
·
E Barr
, CK Gause
, et al.
·
Journal of Lower Genital Tract Disease
·
3
Effects of quadrivalent human papillomavirus vaccination – Authors' reply
2007
·
K Ault
, R Insinga
, et al.
·
The Lancet
·
3
Pcn193 Cost-effectiveness Analysis of Pembrolizumab in Combination With Platinum Chemotherapy and Pemetrexed for Previously Untreated Patients With Metastatic Non-squamous Non-small Cell Lung Cancer in England
2019
·
T. Harding
, R. Insinga
, et al.
·
Value in Health
·
2
PDF
Cost Minimization Analysis Of Tedizolid For The Treatment Of Acute Bacterial Skin And Skin Sub-Structure Infections (Absssi) In Greece
2016
·
R Insinga
, E Dalakaki
, et al.
·
Value in Health
·
2
Pcn116 Cost-effectiveness of Pembrolizumab (keytruda®) Plus Platinum-pemetrexed for First-line Treatment of Metastatic Non-squamous Non-small Cell Lung Cancer in France
2019
·
C. Chouaid
, L. Bensimon
, et al.
·
Value in Health
·
1
THU0629 The Cost-Effectiveness of Golimumab as An Add-on To Conventional Care Compared To CC for The Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland
2016
·
R.H. Borse
, E. McCann
, et al.
·
Annals of the Rheumatic Diseases
·
1
Hospital budget impact of sugammadex (Bridionâ®) for Reversal of Neuromuscular Blockade
2015
·
R. Insinga
, E.M. Maiese
, et al.
·
Value in Health
·
1
PMS9 Budget Impact of Using Sugammadex for the Routine Reversal of Neuromuscular Blockade in a Greek Health Care Setting
2012
·
R.P. Insinga
, T. Konstantopoulou
, et al.
·
Value in Health
·
1
Pin24 the Cost-effectiveness of a Quadrivalent Human Papillomavirus Vaccine (6, I 1,6, 18) in Norway
2007
·
E Dasbach
, E Elbasha
, et al.
·
Value in Health
·
1
Trends in homicide in Wisconsin, 1985-1998.
2001
·
R Insinga
, C Her
, et al.
·
PubMed
·
1
EE203 Number Needed to Treat and Cost of Preventing an Event Analysis for Pembrolizumab in Non-Squamous Metastatic Non-Small Cell Lung Cancer in Colombia
2024
·
V Wurcel
, J. Urrego-Reyes
, et al.
·
Value in Health
PDF
MO01.19 An Indirect Comparison of Pembrolizumab Monotherapy Versus Ipilimumab+Nivolumab for First-Line Metastatic NSCLC with PD-L1 TPS≥1%
2021
·
B. Halmos
, T. Burke
, et al.
·
Journal of Thoracic Oncology
PDF
MO01.18 An indirect Comparison of Pembrolizumab+Chemo vs Ipilimumab+Nivolumab as First-Line Therapies in Patients with PD-L1 TPS≥1% Metastatic NSCLC
2021
·
B. Halmos
, T. Burke
, et al.
·
Journal of Thoracic Oncology
Pcn106 a Review of Cost-effectiveness Studies of Pembrolizumab for the Treatment of Non-small Cell Lung Cancer
2020
·
N. Qiao
, R. Insinga
, et al.
·
Value in Health
Pcn34 - Pembrolizumab Plus Chemotherapy for First-line Treatment of Metastatic Non-squamous Nsclc – a Network Meta-analysis
2018
·
A.M. Frederickson
, S. Arndorfer
, et al.
·
Value in Health
The Cost Effectiveness of Golimumab as an Add-on to Conventional Care Compared to Cc for the Treatment of Non-radiographic Axial Spondyloarthritis in Scotland
2016
·
R.H. Borse
, E. McCann
, et al.
·
Value in Health
Reversal of Neuromuscular Blockade: A Discrete Event Simulation Model of Clinical and Operating Room Efficiency Outcomes of Sugammadex Versus Neostigmine In Canada
2015
·
R Insinga
, C Joyal
, et al.
·
Value in Health
Comparison Of Two Agents For The Reversal Of Neuromuscular Blockade: A Discrete Event Simulation Model Of Operating Room Efficiency In Canada
2014
·
A. Goyette
, R.P. Insinga
, et al.
·
Value in Health
Show more works
View as search
Works count:
31
Citation count:
182
H-index:
6
I10-index:
3
Year
Topic
Type
